Orlistat

奥利司他

Report date: 2022/01/14 13:23:58
NMEFirst In Class

Base Information

Drug NameOrlistat
Drug Alias NameTetrahydrolipstatin奥利斯特OrlistatumAlli赛尼可 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGastric lipase inhibitors
TargetsGastric lipase
Therapy Area/IndicationsOverweightWeight LossObesity +[12] 
Global Approved IndicationsObesity
Approved Indications in ChinaObesity
Original Approved Country/TerritoryEU
Original Approved Date1998/07/29
Country/TerritoryUnited StatesSwedenRussian Federation +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of Texas Southwestern Medical CenterRoche Pharma (Switzerland) LtdEmpros Pharma +[4] 
Inactive CompaniesRoche Pharma AgGlaxosmithkline PlcYale University +[8] 
Active IndicationsObesityHypertriglyceridemiaHyperlipoproteinemia Type I
Inactive IndicationsOverweightWeight LossDiabetes Mellitus +[9] 

Other Information

ATC CodeA08AB01
Related LinksWikipediaDrugBankKEGG